Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07218003 |
| Title | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 |
| Recruitment | Enrolling by invitation |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Rondo Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| START Midwest | Grand Rapids | Michigan | 49546 | United States | Details | |
| Carolina Biooncology | Huntersville | North Carolina | 28078 | United States | Details | |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | United States | Details | |
| Sarah Cannon Research Institute, LLD | Nashville | Tennessee | 37203 | United States | Details | |
| START Center for Cancer Research | San Antonio | Texas | 78229 | United States | Details | |
| START Mountain Region | West Valley City | Utah | 84119 | United States | Details | |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | United States | Details |